For a patient with hypertension and headaches who is taking nebivolol 5 mg daily and hydrochlorothiazide 25 mg daily but still has elevated blood pressure, what should be the next management step?

Add an ACE Inhibitor or ARB to Your Current Regimen

You should add an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as a third agent to the current beta-blocker (nebivolol) and thiazide diuretic (hydrochlorothiazide) regimen. This patient has uncontrolled hypertension at 152/83 mmHg despite dual therapy, requiring escalation to triple-drug therapy according to evidence-based guidelines.

Why This Approach

The 2020 International Society of Hypertension guidelines provide clear algorithmic guidance for non-Black patients with uncontrolled hypertension 1. The standard progression is:

1. Start with ACEI/ARB (first-line)
2. Add a calcium channel blocker (CCB) or thiazide diuretic
3. Add the third drug class not yet used
4. Consider spironolactone or alternatives as fourth-line

Your patient is currently on nebivolol (a beta-blocker) plus hydrochlorothiazide (a thiazide diuretic). This is not the guideline-recommended initial combination - beta-blockers are not first-line for uncomplicated hypertension in most guidelines 1. However, since the patient is already on this regimen, the practical next step is to add the missing cornerstone drug class.

Specific Recommendations

Immediate Action

• Add an ACEI (such as lisinopril 10 mg daily or ramipril 5 mg daily) OR
• Add an ARB (such as losartan 50 mg daily or telmisartan 40 mg daily)

Start at low doses and titrate upward as needed 1.

Target Blood Pressure

• Aim for <130/80 mmHg (optimal target per ISH 2020 guidelines) 1
• Minimum acceptable target: <140/90 mmHg 1
• Achieve target within 3 months of treatment adjustment 1

Critical Considerations Before Adding Medication

1. Verify True Treatment Resistance

Before intensifying therapy, confirm this is genuine uncontrolled hypertension 2:

• Check medication adherence - this is the most common cause of apparent treatment failure
• Confirm with home BP monitoring or 24-hour ambulatory monitoring to exclude white-coat effect 1
• Assess proper BP measurement technique - use validated device, appropriate cuff size, patient seated quietly for 5 minutes 1

2. Optimize Current Medications

The current hydrochlorothiazide dose of 25 mg is appropriate, but consider:

• Nebivolol dose: The patient is on 5 mg daily. According to FDA labeling, this can be increased to 10 mg, 20 mg, or even 40 mg daily if needed 3. However, increasing beta-blocker dose is not the preferred strategy when triple therapy is indicated.

3. Screen for Secondary Hypertension

Given persistent elevation despite dual therapy, evaluate for 1, 2:

• Primary aldosteronism (especially relevant given headaches)
• Obstructive sleep apnea (ask about snoring, daytime sleepiness)
• Renal artery stenosis
• Medication interference - NSAIDs, decongestants, oral contraceptives 4, 2

4. Address Lifestyle Factors

Ensure optimization of 1, 5:

• Sodium intake <2000 mg (5 g salt) daily
• Weight management if overweight
• Alcohol limitation to ≤2 drinks/day for men, ≤1 for women
• Regular aerobic exercise

Alternative Consideration: Medication Substitution

Given that the current regimen doesn't follow guideline-recommended drug classes, you could alternatively consider:

Replace nebivolol with a calcium channel blocker (such as amlodipine 5-10 mg daily) while continuing hydrochlorothiazide, then add an ACEI/ARB. This would create the guideline-preferred triple combination of ACEI/ARB + CCB + thiazide diuretic 1.

However, if the patient has been tolerating nebivolol well and there's a specific indication for beta-blockade (such as coronary disease, heart failure, or atrial fibrillation), keeping it may be reasonable while adding the ACEI/ARB as the third agent.

If Blood Pressure Remains Uncontrolled

Should BP remain elevated after adding an ACEI/ARB and optimizing doses:

Fourth-Line Options (Resistant Hypertension)

The 2025 AHA/ACC guidelines and 2018 AHA Scientific Statement provide clear guidance 4, 2:

1. First choice: Add spironolactone 25-50 mg daily (if eGFR ≥45 mL/min/1.73 m² and potassium <4.5 mmol/L) 4, 2

   • Most effective fourth-line agent
   • Monitor potassium and renal function closely

2. If spironolactone contraindicated or not tolerated:

   • Amiloride 10-20 mg daily 2
   • Doxazosin (alpha-blocker)
   • Additional beta-blocker dose increase (if not already maximized)
   • Clonidine 1, 4

When to Refer

Consider referral to hypertension specialist if 1, 4:

• BP remains uncontrolled on 4+ medications
• Suspected secondary hypertension
• Rapid BP rise or hypertensive emergency features

Common Pitfalls to Avoid

1. Don't combine ACEI + ARB - this combination is not recommended and increases adverse events without additional benefit 5

2. Don't abruptly stop nebivolol - beta-blockers require gradual tapering to avoid rebound hypertension or cardiac events 3

3. Monitor for hyperkalemia when combining ACEI/ARB with spironolactone (if eventually needed) 6, 4

4. Don't assume treatment failure without confirming adherence - non-adherence is the most common cause of apparent resistant hypertension 2

5. Beware drug interactions - nebivolol interacts with CYP2D6 inhibitors, calcium channel blockers (especially verapamil/diltiazem), and digoxin 3

Addressing the Headaches

While optimizing BP control, note that:

• Headaches may improve with better BP control
• However, some antihypertensives (including CCBs if added later) can cause headaches
• If headaches persist despite BP control, investigate other causes

The evidence strongly supports adding an ACEI or ARB as the next logical step, with close follow-up in 2-4 weeks to assess response and tolerability.